NasdaqGS:EWTXPharmaceuticals
Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data
Clinical update sharpens focus on Edgewise Therapeutics stock
Edgewise Therapeutics (EWTX) is back in the spotlight after positive long term MESA extension data suggested stable function in Becker muscular dystrophy patients on sevasemten, drawing fresh attention to the company’s broader muscle disorder pipeline.
See our latest analysis for Edgewise Therapeutics.
The clinical update lands after a strong run in the shares, with a 30 day share price return of 17.40% and a year to date share...